Opinion|Videos|March 1, 2024
Recent Data from KATHERINE and APHINITY in HER2+ Breast Cancer
Author(s)Carey K. Anders, MD
Following SABCS 2023, Carey K. Anders, MD, reviews recent updates from the KATHERINE and APHINITY clinical trials in HER2+ breast cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
2
Changing Mindsets and Removing Guilt Surrounding Lung Cancer Diagnoses
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care
5